Long-term survivors of Hodgkin lymphoma face significant risks of cardiovascular disease related to their cancer therapy, highlighting the need for screening and aggressive management of traditional cardiac risk factors.
No takes yet. Share an insight, caveat, or question.
Supports cardiac risk monitoring in Hodgkin survivors; leaves open optimal screening protocols for prospective trials.
Andrea K. Ng (2011) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: